BR112022025117A2 - 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1 - Google Patents

2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1

Info

Publication number
BR112022025117A2
BR112022025117A2 BR112022025117A BR112022025117A BR112022025117A2 BR 112022025117 A2 BR112022025117 A2 BR 112022025117A2 BR 112022025117 A BR112022025117 A BR 112022025117A BR 112022025117 A BR112022025117 A BR 112022025117A BR 112022025117 A2 BR112022025117 A2 BR 112022025117A2
Authority
BR
Brazil
Prior art keywords
mcl
inhibitors
enamide
macrocyclic
fluoro
Prior art date
Application number
BR112022025117A
Other languages
English (en)
Inventor
Jerhaoui Soufyan
Jan Rita Rombouts Frederik
Stanislas Marcella Diels Gaston
Surkyn Michel
Dominique Jouffroy Matthieu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022025117A2 publication Critical patent/BR112022025117A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

2-AMINO-3-FLUORO-BUT-3-ENAMIDAS MACROCÍCLICAS COMO INIBIDORES DE MCL-1. A presente invenção refere-se a agentes farmacêuticos úteis para terapia e/ou profilaxia de um indivíduo, à composição farmacêutica que compreende tais compostos (fórmula (I)), e ao seu uso como inibidores de MCL-1, úteis para tratamento de doenças tais como câncer.
BR112022025117A 2020-06-10 2021-06-09 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1 BR112022025117A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20179237 2020-06-10
PCT/EP2021/065483 WO2021250102A1 (en) 2020-06-10 2021-06-09 Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1

Publications (1)

Publication Number Publication Date
BR112022025117A2 true BR112022025117A2 (pt) 2022-12-27

Family

ID=71083532

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025117A BR112022025117A2 (pt) 2020-06-10 2021-06-09 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1

Country Status (10)

Country Link
US (1) US20230219906A1 (pt)
EP (1) EP4165050A1 (pt)
JP (1) JP2023528965A (pt)
KR (1) KR20230023008A (pt)
CN (1) CN115698023A (pt)
AU (1) AU2021288987A1 (pt)
BR (1) BR112022025117A2 (pt)
CA (1) CA3180387A1 (pt)
MX (1) MX2022015813A (pt)
WO (1) WO2021250102A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021648A2 (pt) 2018-05-14 2021-01-26 Gilead Sciences, Inc. inibidores de mcl-1
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
KR20220105661A (ko) 2019-11-26 2022-07-27 길리애드 사이언시즈, 인코포레이티드 Mcl1 억제제를 제조하기 위한 방법 및 중간체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) * 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
US11364248B2 (en) 2017-08-18 2022-06-21 Amgen Inc. Compounds that inhibit Mcl-1 protein
EP3676270A1 (en) 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
US11274105B2 (en) 2018-03-05 2022-03-15 Amgen Inc. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists
BR112020021648A2 (pt) * 2018-05-14 2021-01-26 Gilead Sciences, Inc. inibidores de mcl-1
CN113166173A (zh) 2018-11-09 2021-07-23 普莱鲁德疗法有限公司 作为骨髓细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物
EP3771469A1 (en) 2019-07-30 2021-02-03 Amgen, Inc Formulations and dosages for administering a compound that inhibits mcl1 protein

Also Published As

Publication number Publication date
JP2023528965A (ja) 2023-07-06
KR20230023008A (ko) 2023-02-16
CA3180387A1 (en) 2021-12-16
WO2021250102A1 (en) 2021-12-16
CN115698023A (zh) 2023-02-03
US20230219906A1 (en) 2023-07-13
EP4165050A1 (en) 2023-04-19
MX2022015813A (es) 2023-01-24
AU2021288987A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022005627A2 (pt) Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto
BR112023022451A2 (pt) Composto triazina substituído
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BR112023015590A2 (pt) Antagonistas de gpr84 e usos dos mesmos
CO2023013469A2 (es) Derivados de fósforo como nuevos inhibidores de sos1
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
BR112023025916A2 (pt) Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
BR112022013488A2 (pt) Pirazolo-pirimidinas substituídas e seu uso
BR112022009754A2 (pt) Derivados macrocíclicos de sulfonila como inibidores de mcl-1
BR112022009142A2 (pt) Derivados de indol macrocíclicos como inibidores de mcl-1
BR112021020405A2 (pt) Benzo- e pirido-pirazóis como inibidores de proteína quinase
BR112023020877A2 (pt) 2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1